SWIFTWATER, Pa., Oct. 14 (UPI) -- U.S. clinical trials of the new H1N1 swine flu vaccine indicates that two doses may be needed to protect children under 10, its maker said Wednesday.
Sanofi Pasteur of Swiftwater, Pa., said in a release that interim analysis of data from clinical trials of the vaccine in children showed that while one dose may protect many children, two doses of vaccine will be required for optimal protection of children under the age of 10 years.
The company, which produces approximately 40 percent of the influenza vaccines distributed worldwide, said clinical trials are ongoing to evaluate safety in children following two doses of vaccine.
"According to the Centers for Disease Control and Prevention young children are among those of highest priority for immunization with the Influenza A (H1N1) 2009 Monovalent Vaccine, given the relatively high disease incidence and potential for transmission in this population," Sanofi Pasteur president Wayne Pisano said.
